Sandra Milligan
Insider Reports History
- Location
- San Diego, CA
- Signature
- /s/ Jeff Boerneke, Attorney-in-Fact
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by Sandra Milligan:
| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Organon & Co. | Head of Research & Development | Common Stock | 28,599 | $615,736 | $21.53 | 04 May 2023 | Direct |
| Gossamer Bio, Inc. | Director | Common Stock | 58,050 | $111,456 | $1.92 | 19 Aug 2025 | Direct |
| Organon & Co. | Head of Research & Development | Restricted Stock Units | 4,984 | $107,306 | $21.53 | 04 May 2023 | Direct |
| Aspira Women's Health Inc. | Interim CEO | Stock option (right to buy) | 25,000 | $96,000 | $3.20 | 12 Nov 2024 | Direct |
| Aspira Women's Health Inc. | Interim CEO | Common Stock | 13,644 | $9,551 | $0.7000 | 08 Jan 2025 | Direct |
| Aspira Women's Health Inc. | Interim CEO | Restricted Stock Units | 0 | $0 | $2.42 | 31 Dec 2024 | Direct |
| Gossamer Bio, Inc. | Director | Stock Option (Right to Buy) | 115,000 | 25 Jun 2025 | Direct | ||
| Spyre Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 25,000 | 29 May 2025 | Direct |
Insider Reports Filed by Sandra Milligan
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | 19 Aug 2025 | 1 | +$50,016 | 4 | Director | 20 Aug 2025, 16:04 |
| GOSS | Gossamer Bio, Inc. | 25 Jun 2025 | 1 | $0 | 4 | Director | 26 Jun 2025, 16:36 |
| SYRE | Spyre Therapeutics, Inc. | 29 May 2025 | 1 | $0 | 4 | Director | 02 Jun 2025, 16:37 |
| AWHL | Aspira Women's Health Inc. | 31 Dec 2024 | 3 | -$4,449 | 4/A | Interim CEO | 29 Jan 2025, 17:20 |
| AWHL | Aspira Women's Health Inc. | 12 Nov 2024 | 1 | $0 | 4 | President | 13 Nov 2024, 20:54 |
| AWHL | Aspira Women's Health Inc. | 28 Oct 2024 | 1 | $0 | 4 | President | 28 Oct 2024, 18:54 |
| GOSS | Gossamer Bio, Inc. | 06 Jun 2024 | 1 | $0 | 4 | Director | 06 Jun 2024, 21:58 |
| SYRE | Spyre Therapeutics, Inc. | 14 May 2024 | 1 | $0 | 4 | Director | 16 May 2024, 16:10 |
| SYRE | Spyre Therapeutics, Inc. | 14 May 2024 | 0 | $0 | 3 | Director | 16 May 2024, 16:05 |
| AWHL | Aspira Women's Health Inc. | 03 May 2024 | 1 | $0 | 4 | President | 06 May 2024, 18:49 |
| AWHL | Aspira Women's Health Inc. | 01 Apr 2024 | 0 | $0 | 3 | President | 04 Apr 2024, 19:27 |
| GOSS | Gossamer Bio, Inc. | 15 Nov 2023 | 1 | +$25,213 | 4 | Director | 17 Nov 2023, 16:01 |
| GOSS | Gossamer Bio, Inc. | 08 Jun 2023 | 1 | $0 | 4 | Director | 09 Jun 2023, 16:14 |
| OGN | Organon & Co. | 04 May 2023 | 3 | -$52,552 | 4 | Head of Research & Development | 08 May 2023, 18:43 |
| OGN | Organon & Co. | 01 May 2023 | 3 | -$20,344 | 4 | Head of Research & Development | 03 May 2023, 19:06 |
| OGN | Organon & Co. | 31 Mar 2023 | 5 | -$48,835 | 4 | Head of Research & Development | 04 Apr 2023, 20:18 |
| OGN | Organon & Co. | 28 Feb 2023 | 3 | -$58,861 | 4 | Head of Research & Development | 02 Mar 2023, 16:29 |
| GOSS | Gossamer Bio, Inc. | 09 Jun 2022 | 1 | $0 | 4 | Director | 15 Jul 2022, 17:03 |
| OGN | Organon & Co. | 03 May 2022 | 6 | -$75,429 | 4 | Head of Research & Development | 05 May 2022, 20:47 |
| OGN | Organon & Co. | 01 May 2022 | 3 | -$17,458 | 4 | Head of Research & Development | 03 May 2022, 19:40 |
| OGN | Organon & Co. | 31 Mar 2022 | 2 | $0 | 4 | Head of Research & Development | 04 Apr 2022, 18:06 |
| OGN | Organon & Co. | 28 Feb 2022 | 3 | -$110,493 | 4 | Head of Research & Development | 02 Mar 2022, 17:46 |
| OGN | Organon & Co. | 17 Aug 2021 | 1 | $0 | 4 | Head of Research & Development | 19 Aug 2021, 17:14 |
| GOSS | Gossamer Bio, Inc. | 10 Jun 2021 | 1 | $0 | 4 | Director | 14 Jun 2021, 17:26 |
| GOSS | Gossamer Bio, Inc. | 10 Jun 2021 | 0 | $0 | 3 | Director | 14 Jun 2021, 17:21 |
| OGN | Organon & Co. | 02 Jun 2021 | 12 | $0 | 4 | Head of Research & Development | 04 Jun 2021, 21:27 |
| OGN | Organon & Co. | 02 Jun 2021 | 0 | $0 | 3 | Head of Research & Development | 02 Jun 2021, 17:48 |